RxDoctor Payments Data

Paul Cunningham, MD

Interventional Cardiology · Shenandoah, TXNPI 1356582886

Payments from drug & device makers

$25,180in general payments, 2019–2025

Across 794 payments — averaging $31.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abbott$4K
  • Amgen$2K
  • Novartis$1K
  • Boston Scientific$1K
  • Avinger Inc.$1K
  • plus $10K from 54 others

What the payments were for

  • Travel & lodging$1,9978%
  • Food & beverage$23,06892%
  • Education$1150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)46$4,636
Abbott73$4,382
Amgen160$2,070
Novartis104$1,494
Boston Scientific47$1,440
Avinger Inc.20$1,120
E.r. Squibb & Sons, L.L.C.36$835
Abiomed7$684
Shockwave Medical, Inc15$666
Smith+Nephew28$624
Siemens Medical Solutions USA, Inc.11$584
Boehringer Ingelheim17$513
Johnson & Johnson28$463
Impulse Dynamics (USA) Inc.11$416
Merck25$394
Inari Medical, Inc.5$361
Pfizer9$261
Esperion Therapeutics, Inc.8$257
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)6$252
Actelion Pharmaceuticals US, Inc.6$242
Atricure, Inc.5$231
Corindus Inc.2$222
Cvrx, Inc.6$210
Sanofi-aventis U.S. LLC14$194
Surmodics, Inc.2$184
Angiodynamics, Inc.3$169
Vifor Pharma, Inc.2$138
Heartflow, Inc.8$135
Regeneron1$129
AstraZeneca9$128
Tactile Systems Technology Inc9$123
Philips North America LLC2$117
Venclose Inc.2$91
Elutia, Inc.4$75
Biotronik Inc.4$73
Kestra Medical Technology Services, Inc.1$73
Regeneron Healthcare Solutions, Inc.3$72
Imperative Care, Inc1$67
Amarin Pharma, Inc.4$67
LEO Pharma Inc.1$63
G Medical Diagnostic Services, Inc.4$60
Endologix LLC1$55
Urgo Medical North America, LLC2$52
GE HealthCare4$52
Chiesi USA, Inc.3$47
Biosense Webster, Inc.2$46
Lemaitre Vascular, Inc.2$36
Terumo Medical Corporation1$35
Baxter Healthcare1$34
Bardy Diagnostics, Inc.2$30
Kowa Pharmaceuticals America, Inc.2$30
Cardiva Medical, Inc.1$30
LSI Solutions Inc1$29
Edwards Lifesciences1$28
Coloplast1$27
Biocompatibles, Inc.2$26
Bard Peripheral Vascular, Inc.2$24
Astellas Pharma US Inc1$23
Silk Road Medical, Inc.1$22
Lantheus Medical Imaging, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,180 in reported general payments places this provider in the 70th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$453,458
Medicare patients
1,887
Services billed
4,967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban774$837,241
XareltoRivaroxaban349$400,387
Repatha SureclickEvolocumab198$233,876
EntrestoSacubitril/Valsartan78$92,620
JardianceEmpagliflozin65$79,703
Praluent PenAlirocumab54$43,843
Repatha SyringeEvolocumab26$40,548
BrilintaTicagrelor46$35,127
FarxigaDapagliflozin Propanediol29$32,015
Repatha PushtronexEvolocumab16$19,270
MultaqDronedarone Hcl13$18,812
Valsartan456$15,757
Metoprolol Succinate894$13,535
Nifedipine ErNifedipine327$12,485
Atorvastatin Calcium1,037$9,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$261$837,241774 claims
Johnson & JohnsonXarelto$463$400,387349 claims
NovartisEntresto$1,494$92,62078 claims
Boehringer IngelheimJardiance$513$79,70365 claims
AstraZenecaBrilinta, Farxiga$128$67,14275 claims
Sanofi-aventis U.S. LLCMultaq$194$18,81213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →